ALK and non-small cell lung carcinoma: Another real-world dataset from the US GuardantINFORM database suggests that among ALK fusion-positive NSCLC patients receiving second- or third-generation ALK-TLI therapy, those with concurrent TP53 mutations experienced significantly shorter Time to Disease Progression (TTD) compared to those without detectable TP53 mutations (13.1 months vs. 27.6 months, HR = 1.53, 95% CI: 1.07-2.19, p=0.0202) (13).